Polynovo Stock

Polynovo EBIT Margin

The EBIT Margin (Operating Margin) of Polynovo (PNV.AX) as of Aug 1, 2026 is 3.89 %. In the previous year, EBIT Margin (Operating Margin) was 2.58 % — a change of 51.07% (higher).

EBIT Margin

3.89 %

YoY

51.07%

Last updated:

EBIT Margin (Operating Margin) of Polynovo is 2026 3.89 % . EBIT Margin (Operating Margin) of Polynovo was 2025 2.58 % . It decreases by 51.07% higher compared to the previous year.

Polynovo's operating (EBIT) margin stands at 3.9%, up from -10.8% several years earlier.

Access this data via the Eulerpool API

Polynovo Stock analysis

What does Polynovo do? Polynovo Ltd is an Australian BioTech company that specializes in the development and manufacturing of medical implants. The company was founded in 1986 under the name Regeneus Ltd and is headquartered in Melbourne. Polynovo's history began with the development of products for the veterinary field. In 2000, the company received approval for the sale of its first human products, which were used for wound treatment. In 2014, the company was renamed Polynovo to emphasize its focus on biological implants for human tissue. Polynovo utilizes a revolutionary technology called NovoSorb, which allows for the production of biodegradable polymer films in various shapes and sizes. These are then used as implants in the human body and naturally degrade within a predetermined timeframe. Polynovo is divided into various divisions, including wound care, plastic surgery, and orthopedics. In wound care, the company offers products that aim to prevent infections and promote natural healing processes. The plastic surgery division provides implants for breast reconstruction and fat transplantation. In orthopedics, Polynovo manufactures implants for joints, bones, and tendons. An example of a Polynovo product is NovoSorb BTM (Biodegradable Temporary Matrix), which is used in burns and other skin defects. The matrix stimulates healing and the formation of new tissue, restoring a normal appearance to the patient. Polynovo's business model is based on long-term relationships with hospitals, medical professionals, and government agencies. The company heavily invests in research and development to continuously improve and expand its technology and product range. Through partnerships with other companies and academic institutions, Polynovo is working towards global distribution of its products. Overall, Polynovo has received various awards over the years, including an innovation award from the Australian Trade Commission, and has been recognized multiple times as one of Australia's fastest-growing companies. In conclusion, Polynovo is an innovative and successful company specializing in the development and manufacturing of biological implants. Thanks to its NovoSorb technology, the company can offer products that help accelerate the healing process and facilitate faster patient recovery. Polynovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polynovo stock

EBIT Margin (Operating Margin) of Polynovo is 3.89 % in 2026.

Access this data via the Eulerpool API

Margins — Polynovo

All Key Metrics — Polynovo